MX2009000243A - Medicamento para la mejora de la funcion cognoscitiva y neuroproteccion. - Google Patents

Medicamento para la mejora de la funcion cognoscitiva y neuroproteccion.

Info

Publication number
MX2009000243A
MX2009000243A MX2009000243A MX2009000243A MX2009000243A MX 2009000243 A MX2009000243 A MX 2009000243A MX 2009000243 A MX2009000243 A MX 2009000243A MX 2009000243 A MX2009000243 A MX 2009000243A MX 2009000243 A MX2009000243 A MX 2009000243A
Authority
MX
Mexico
Prior art keywords
memory
cognitive function
pyridazinone
benz
piperidin
Prior art date
Application number
MX2009000243A
Other languages
English (en)
Inventor
Hajnalka Kompagne
Gyula Simig
Gabor Gigler
Istvan Gacsalyi
Marta Agoston
Szabolcs Kertesz
Krisztina Moricz
Gyoergy Levay
Laszlo Gabor Harsing
Gabor Szenasi
Jozsef Barkoczy
Original Assignee
Egis Gyogyszergyar Nyilvanosan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gyogyszergyar Nyilvanosan filed Critical Egis Gyogyszergyar Nyilvanosan
Publication of MX2009000243A publication Critical patent/MX2009000243A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere al uso de 4- cloro-5-{2-[4-(6-fluoro-1,2-b enz[djisoxazol-3-- il)piperidin-1-il]etil-amino}-2-metil-3-(2H) piridazinona de la Fórmula (1) o sales farmacéuticamente aceptables de la misma para la preparación de medicamentos adecuados para la mejora de la función cognoscitiva o la obtención del efecto neuroprotector. Los medicamentos que contienen 4-cloro-5-{2-[4-(6- fluoro-l,2-benz[d]isoxazol-3-il)pipe ridin-l- il]etil-amino}--2-metil-3-(2H) piridazinona de la Fórmula (1) o sal farmacéuticamente aceptable de la misma podrán utilizarse para el tratamiento o la prevención de muerte neuronal, deterioro mental, esclerosis múltiple, enfermedad de Creuzfeld-Jacobs, síndrome de Huntingdon, esclerosis lateral amiotráfica, enfermedad de Parkinson, trastorno mental, pérdida de la memoria, amnesia, apoplejía o para la mejora de función de la memoria o habilidad de aprendizaje.
MX2009000243A 2006-07-03 2007-07-03 Medicamento para la mejora de la funcion cognoscitiva y neuroproteccion. MX2009000243A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0600555A HUP0600555A3 (en) 2006-07-03 2006-07-03 Use of 4-chloro-5-{2-[4-(6-fluoro-1,2-benz[d]izoxazol-3-yl)piperidin-1-yl]ethylamino}2-methyl-3(2h)-piridazinon for the production of pharmaceutical compositions for influencing cognitive functions and causing neuroprotective effect
PCT/HU2007/000059 WO2008004013A2 (en) 2006-07-03 2007-07-03 Medicament for the enhancement of cognitive function and neuroprotection

Publications (1)

Publication Number Publication Date
MX2009000243A true MX2009000243A (es) 2009-07-22

Family

ID=89986887

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000243A MX2009000243A (es) 2006-07-03 2007-07-03 Medicamento para la mejora de la funcion cognoscitiva y neuroproteccion.

Country Status (26)

Country Link
US (1) US8318743B2 (es)
EP (1) EP2049113B8 (es)
JP (1) JP5174018B2 (es)
KR (1) KR101465415B1 (es)
CN (1) CN101516373B (es)
AT (1) ATE468854T1 (es)
AU (1) AU2007270910B2 (es)
BR (1) BRPI0713395A2 (es)
CA (1) CA2656549C (es)
CY (1) CY1110741T1 (es)
DE (1) DE602007006813D1 (es)
DK (1) DK2049113T3 (es)
EA (1) EA016142B1 (es)
HK (1) HK1131032A1 (es)
HR (1) HRP20100465T1 (es)
HU (1) HUP0600555A3 (es)
IL (1) IL196315A (es)
MA (1) MA30951B1 (es)
MX (1) MX2009000243A (es)
NZ (1) NZ574596A (es)
PL (1) PL2049113T3 (es)
PT (1) PT2049113E (es)
RS (1) RS51429B (es)
SI (1) SI2049113T1 (es)
WO (1) WO2008004013A2 (es)
ZA (1) ZA200900507B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9602763A3 (en) 1996-10-09 1999-05-28 Egyt Gyogyszervegyeszeti Gyar 3-phenyl isoxazole derivatives, process for producing them and pharmaceutical compositions containing the same
WO2001017993A1 (en) 1999-09-09 2001-03-15 EGIS Gyógyszergyár Rt. Alkylpiperidi nylbenzo [d] isoxazole derivatives having psychotropic activity, pharmaceutical compositions containing the same, and a process for the preparation of the active ingredient
HU225955B1 (en) * 2001-07-26 2008-01-28 Egis Gyogyszergyar Nyilvanosan Novel 2h-pyridazin-3-one derivatives, process for their preparation, their use and pharmaceutical compositions containing them
US20030024849A1 (en) * 2001-07-26 2003-02-06 Nielsen Jacob Sturich Package for blister pack strips
HU227118B1 (en) * 2001-11-13 2010-07-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of 3-{2-[4-(6-fluoro-1,2-benzizoxazol-3-yl)-1-piperidinyl]-ethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one
HU227255B1 (en) * 2002-04-26 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Novel piperidine-alkyl-amino-pyridazine derivatives, pharmaceutical compositions containing the same and process for the preparation of the active ingredient

Also Published As

Publication number Publication date
EA016142B1 (ru) 2012-02-28
AU2007270910B2 (en) 2012-08-09
JP2009542614A (ja) 2009-12-03
JP5174018B2 (ja) 2013-04-03
MA30951B1 (fr) 2009-12-01
CN101516373A (zh) 2009-08-26
KR101465415B1 (ko) 2014-11-26
PL2049113T3 (pl) 2011-02-28
NZ574596A (en) 2012-12-21
DK2049113T3 (da) 2010-08-16
AU2007270910A1 (en) 2008-01-10
HU0600555D0 (en) 2006-09-28
PT2049113E (pt) 2010-08-26
ATE468854T1 (de) 2010-06-15
CA2656549C (en) 2014-07-22
HRP20100465T1 (hr) 2010-10-31
WO2008004013A2 (en) 2008-01-10
US20100075975A1 (en) 2010-03-25
WO2008004013A3 (en) 2008-04-03
CY1110741T1 (el) 2014-02-12
HK1131032A1 (en) 2010-01-15
RS51429B (en) 2011-04-30
WO2008004013A8 (en) 2009-07-02
ZA200900507B (en) 2010-05-26
DE602007006813D1 (de) 2010-07-08
EP2049113B1 (en) 2010-05-26
CN101516373B (zh) 2012-09-12
SI2049113T1 (sl) 2010-10-29
CA2656549A1 (en) 2008-01-10
IL196315A0 (en) 2009-09-22
EP2049113B8 (en) 2010-11-03
EA200900088A1 (ru) 2009-12-30
IL196315A (en) 2014-09-30
HUP0600555A2 (en) 2008-09-29
EP2049113A2 (en) 2009-04-22
BRPI0713395A2 (pt) 2012-04-17
KR20090091686A (ko) 2009-08-28
US8318743B2 (en) 2012-11-27
HUP0600555A3 (en) 2008-10-28

Similar Documents

Publication Publication Date Title
JP5115474B2 (ja) 消化管潰瘍治療又は予防薬
JP2008513516A5 (es)
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
CA2641473A1 (en) Condensed imidazole derivatives as aldosterone synthase inhibitors
MX2009011830A (es) Compuestos amino-heterociclicos.
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
JP2008513504A5 (es)
NZ592961A (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
MX2012012952A (es) Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina.
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
HK1146049A1 (en) Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
NZ595571A (en) Pyrazole compounds and uses thereof
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
PE20080360A1 (es) Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3
UA85707C2 (ru) Бензоксазины для лечения заболеваний дыхательных путей
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
NZ596154A (en) Cyclic compound having substituted phenyl group
MX2011010732A (es) Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer.
WO2008080988A3 (en) Cyclopentanone derivatives, method of synthesis and uses thereof
ATE357453T1 (de) Comt-inhibitoren
EP2049113B8 (en) Medicament for the enhancement of cognitive function and neuroprotection
WO2009069680A1 (ja) 消化管間質腫瘍（ｇｉｓｔ）を処置するための医薬組成物、ならびに消化管間質腫瘍を患う患者の予後を予測するためのキットおよび方法

Legal Events

Date Code Title Description
FG Grant or registration